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To the Editor,
Cerebrospinal fluid (CSF) concentrations of amyloid β 
peptides 38, 40 and 42 (Aβ38, Aβ40, Aβ42), total tau 
(T-tau) and phosphorylated tau181 (P-tau) are increasingly 
used as biomarkers to support a clinical diagnosis of 
 Alzheimer’s disease (AD), and to track disease progres-
sion in observational research studies and clinical trials 
[1]. It is therefore of great importance to understand the 
analytical repeatability (i.e. the variability of repeated 
measures of the same sample assayed by the same opera-
tor) of currently available enzyme-linked immunosorbent 
assays (ELISAs). In the interest of improving diagnos-
tic reliability within and between sites there is a need to 
identify strategies to reduce analytical variance. Presently 
the U.S. Food and Drugs Administration (FDA) criteria for 
bioanalytical assay precision demands an average percent 
coefficient of variation (%CV) of  < 15% between measure-
ments for a quantitative immunoassay to be regarded as 
having acceptable quality for clinical use [2]. Better ana-
lytical precision will be required to reliably monitor the in 
vivo biomarker responses to disease modifying drugs, and 
detect clinically relevant biomarker changes in patients 
over time, based on reports from longitudinal studies 
(e.g. P-tau 2.20  pg/mL decrease per year, Aβ42 decrease 
11.9 pg/mL per year in AD-AD patients) [3].
The aim of this study was first to measure the ana-
lytical repeatability of ELISA-based assays for amyloid 
peptides and tau; and second to test the hypothesis that 
adding 0.05% Tween 20, a non-ionic surfactant that has 
previously been found to mitigate variation introduced by 
protein-tube surface interactions in CSF Aβ42 measure-
ments [4, 5], would also decrease the variability between 
measurements.
Six de-identified CSF samples, each of 11 mLs, were 
used in this study: three were from individual subjects, 
and three pooled samples formed by mixing 2.2  mL CSF 
from five individual subject samples (Figure 1A and B). All 
samples were collected according to the standard operating 
procedure of the Sahlgrenska Academy at the University of 
Gothenburg (supplementary table in [6]), and with ethical 
approvals from the London Queen Square Ethics Committee 
(individual samples) and University of Gothenburg (pooled 
samples). Each of the six 11 mL CSF samples was split into 
two 5.5 mL samples (Figure 1C) and 2.75 μL (0.05%) Tween 
20 was added to one of these (Figure 1D), following which 
both 5.5 mL samples were aliquoted at 500 μL volume, into 
2 mL, polypropylene, DNase/RNase free tubes (Sarstedt, 
Nümbrecht, Germany, cat. 72.694.406) (Figure 1E). These 
aliquots were then stored at −80 °C. Aβ38, 40 and 42 were 
measured simultaneously in the same assay plate (MSD 
Aβ Peptide Panel 1 V-plex, 6E10 antibody). T-tau was 
measured separately using MSD T-tau V-plex assay. Both 
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Figure 1: Experiment procedure.
Detailed are the various steps of the experiment.
of these assays were run on a Meso Scale Discovery 6000 
platform. P-tau was measured separately by INNOTEST 
Phospho-tau (181P) ELISA and run using a BMG Labtech 
FLUOstar Omega multi-mode microplate reader (Figure 1F). 
In terms of sample layout within plate, each of the (three) 
biomarker assays were treated the same. Each sample was 
added to the plate in three pairs (i.e. six wells total – 1,2 
| 3,4| 5,6), in order to collect intra-assay variation data for 
each sample (Figure 1F). It is common laboratory practice to 
use two wells for each sample (known as running a sample 
‘in duplicate’), and distributing samples in this way was 
intended to simulate this multiple times. Additionally, the 
identity of each sample tube was masked, and renamed in 
a different order by a colleague, thus the experiment was 
conducted under double-blind conditions. The experiment 
was repeated four times (i.e. four plates were run for Aβ, 
T-tau and P-tau) (Figure 1G), in order to collect data on inter-
assay variation. Each repeat took place on a different day, 
and was conducted by the same operator.
To analyse measurement variance, %CVs were calcu-
lated according to ISO standards [7], and the results from 
aliquots with Tween added (‘Tween’) and those without 
(‘No Tween’) were compared using paired t-tests in R [8]. 
To investigate the contribution of covariates, linear 
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mixed model analyses were conducted using the nlme [9] 
package in R. To allow for increasing variance as concen-
tration increased, the dependent variance in all analyses 
was concentration on a log scale (pg/mL). The interaction 
between Tween status and intra-assay sample repeat were 
the independent variables. A random intercept for sample 
was included, as was a random effect of Tween to allow 
for variability in the effect of Tween between samples.
The degree of variability between measurements 
for all samples and for all biomarkers, whether intra- or 
inter-assay, was  < 10% (Table 1), meaning that concen-
tration measurements can be considered highly repeat-
able regardless of Tween 20 status. For measurements of 
Aβ42 in the same sample across different assays, %CVs 
of ‘Tween’ samples were significantly lower than in ‘No 
Tween’ samples (p = 0.04) (Table 1 t-test). Further explora-
tion with the use of linear mixed model analysis revealed 
that this result was driven by individual subject samples, 
whilst variance in pooled samples also decreased but 
did not reach significance (Table 1 Mixed model). No sig-
nificant differences were found in any of the other bio-
markers. Finally, concentration of Aβ peptides increased 
significantly with Tween (Aβ38 = 42% increase, p  ≤  0.0001; 
Aβ40 = 43% increase, p  ≤  0.0001; Aβ42 = 69% increase, 
p  ≤  0.0001). No significant change was observed in the 
detectable concentration of P-tau (p = 0.9), with a trend 
towards an increase in T-tau (p = 0.9).
These results are consistent with data previously 
reported [4, 5], and showed that measurement variation 
was very low in all biomarkers throughout this study. Fur-
thermore, results showed that repeat measurement vari-
ation of Aβ42 in individual subject CSF was improved by 
the addition of 0.05% Tween 20. If this finding generalises 
to datasets with greater levels of analytical variance, e.g. 
multi-site initiatives, it could be of clinical relevance. Fol-
lowing recent setbacks in AD drug development [10], it is 
now widely considered that a longitudinal and collabora-
tive approach to research and clinical trial work in neuro-
degenerative disease is required if meaningful therapeutic 
progress is to be achieved. Reliable measurements are 
essential to such a strategy, and the potential to improve 
this for Aβ42 by adding 0.05% Tween 20 is worth further 
consideration. Despite the number of repeats, a limita-
tion of this study was the small number of samples tested. 
Results should be treated as preliminary, and provide a 
reference effect size to inform future work.
This study shows that ELISA based measurement of 
neurodegenerative biomarkers in CSF treated with and 
without 0.05% Tween 20 can be highly repeatable for indi-
vidual and pooled patient samples given strict standardi-
sation of procedure.
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